Last reviewed · How we verify

Granisetron Transdermal Patch

Gynecologic Oncology Group · FDA-approved active Small molecule Quality 2/100

Granisetron Transdermal Patch is a Small molecule drug developed by Gynecologic Oncology Group. It is currently FDA-approved. Also known as: Granisetron Transdermal System, Sancuso, sancuso.

At a glance

Generic nameGranisetron Transdermal Patch
Also known asGranisetron Transdermal System, Sancuso, sancuso
SponsorGynecologic Oncology Group
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Granisetron Transdermal Patch

What is Granisetron Transdermal Patch?

Granisetron Transdermal Patch is a Small molecule drug developed by Gynecologic Oncology Group.

Who makes Granisetron Transdermal Patch?

Granisetron Transdermal Patch is developed and marketed by Gynecologic Oncology Group (see full Gynecologic Oncology Group pipeline at /company/gynecologic-oncology-group).

Is Granisetron Transdermal Patch also known as anything else?

Granisetron Transdermal Patch is also known as Granisetron Transdermal System, Sancuso, sancuso.

What development phase is Granisetron Transdermal Patch in?

Granisetron Transdermal Patch is FDA-approved (marketed).

Related